Drug treatment of multiple sclerosis.
作者信息
Polman C H, Uitdehaag B M
机构信息
Department of Neurology, Academic Hospital Vrije Universiteit, PO Box 7057, 1007 MB Amsterdam, Netherlands.
出版信息
BMJ. 2000;321(7259):490-4. doi: 10.1136/bmj.321.7259.490.
Abstract
摘要
相似文献
1
Drug treatment of multiple sclerosis.
BMJ. 2000;321(7259):490-4. doi: 10.1136/bmj.321.7259.490.
2
Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon-beta.
Ann Neurol. 1994 Jul;36(1):14-8. doi: 10.1002/ana.410360106.
3
Confounders in natural history of interferon-beta-treated relapsing multiple sclerosis.
Ann Neurol. 2008 Jan;63(1):126; author reply 126-7. doi: 10.1002/ana.21186.
4
Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?
Arch Neurol. 2009 Jan;66(1):19-20. doi: 10.1001/archneurol.2008.529.
5
Magnetic resonance imaging in the evaluation of clinical trials in multiple sclerosis.
Ann Neurol. 1994;36 Suppl:S95-6. doi: 10.1002/ana.410360721.
6
Multiple sclerosis therapy. A practical guide.
Drugs. 1995 Feb;49(2):200-12. doi: 10.2165/00003495-199549020-00005.
7
Interferon beta in multiple sclerosis: how much BENEFIT?
Lancet. 2007 Aug 4;370(9585):363-4. doi: 10.1016/S0140-6736(07)61170-2.
8
[Treatment with beta-interferon should be started already after the first attack of MS].
Lakartidningen. 2001 Feb 7;98(6):587-90, 593-4.
9
Beta interferons for multiple sclerosis.
Med Lett Drugs Ther. 2002 Oct 14;44(1141):88-9.
10
Interferon beta-1a during a first demyelinating event.
N Engl J Med. 2001 Jan 18;344(3):229; author reply 229-30. doi: 10.1056/NEJM200101183440313.
引用本文的文献
1
Inflammatory proteins related to depression in multiple sclerosis: A systematic review and meta-analysis.
Brain Behav Immun Health. 2024 Dec 28;43:100939. doi: 10.1016/j.bbih.2024.100939. eCollection 2025 Feb.
2
2-Bromo-1,4-Naphthalenedione promotes CD8 T cell expansion and limits Th1/Th17 to mitigate experimental autoimmune encephalomyelitis.
J Neuroinflammation. 2024 Jul 27;21(1):181. doi: 10.1186/s12974-024-03172-x.
3
Immune cells transcriptome-based drug repositioning for multiple sclerosis.
Front Immunol. 2022 Oct 20;13:1020721. doi: 10.3389/fimmu.2022.1020721. eCollection 2022.
4
Oxidative Stress and Lymphocyte Alterations in Chronic Relapsing Experimental Allergic Encephalomyelitis in the Rat Hippocampus and Protective Effects of an Ethanolamine Phosphate Salt.
Mol Neurobiol. 2020 Feb;57(2):860-878. doi: 10.1007/s12035-019-01774-8. Epub 2019 Sep 10.
5
Changes in the Multiple Sclerosis Treatment Paradigm. What Do We Do Now and What Were We Doing Before?
J Clin Neurol. 2018 Oct;14(4):487-491. doi: 10.3988/jcn.2018.14.4.487. Epub 2018 Jul 30.
6
Importance of Diffusion Weighted Magnetic Resonance Imaging in Evaluation of the Treatment Efficacy in Multiple Sclerosis Patients with Acute Attacks.
Pol J Radiol. 2015 Dec 17;80:544-8. doi: 10.12659/PJR.895325. eCollection 2015.
7
Blocking A2B adenosine receptor alleviates pathogenesis of experimental autoimmune encephalomyelitis via inhibition of IL-6 production and Th17 differentiation.
J Immunol. 2013 Jan 1;190(1):138-46. doi: 10.4049/jimmunol.1103721. Epub 2012 Dec 5.
8
Effects of adjunct low-dose vitamin d on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial.
Mult Scler Int. 2012;2012:452541. doi: 10.1155/2012/452541. Epub 2012 Apr 11.
9
FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value.
Core Evid. 2006;1(3):157-67. Epub 2006 Mar 31.
10
Disease modifying agents for multiple sclerosis.
Open Neurol J. 2010 May 26;4:15-24. doi: 10.2174/1874205X01004010015.
本文引用的文献
1
Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life.
J Neurol Neurosurg Psychiatry. 2000 Feb;68(2):144-9. doi: 10.1136/jnnp.68.2.144.
2
Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis.
BMJ. 1999 Dec 11;319(7224):1529-33. doi: 10.1136/bmj.319.7224.1529.
3
A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases.
Brain. 1999 Dec;122 ( Pt 12):2279-95. doi: 10.1093/brain/122.12.2279.
4
Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.
Neurology. 1999 Sep 11;53(4):751-7. doi: 10.1212/wnl.53.4.751.
5
Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group.
Neurology. 1999 Sep 11;53(4):679-86. doi: 10.1212/wnl.53.4.679.
6
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis.
Ann Neurol. 1999 Sep;46(3):296-304. doi: 10.1002/1531-8249(199909)46:3<296::aid-ana4>3.0.co;2-#.
7
Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis.
Ann Neurol. 1999 Aug;46(2):197-206. doi: 10.1002/1531-8249(199908)46:2<197::aid-ana9>3.0.co;2-p.
8
9
10
The role of magnetic resonance techniques in understanding and managing multiple sclerosis.
Brain. 1998 Jan;121 ( Pt 1):3-24. doi: 10.1093/brain/121.1.3.
Zotero 插件